Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients
For many years, researchers and doctors have studied different kinds of treatments to improve the survival of men with testicular cancer. However, recent research has shown that many years later, men who had testicular cancer appear to be at higher risk for developing heart disease (heart attack or heart failure), especially if they received chemotherapy. Since these studies were done many years after men received treatment, there was no way to know if other factors contributed to the health problems they experienced. This study is being done because it would be helpful to study heart function and cardiovascular disease risk factors of men who have been diagnosed with testicular cancer, before and after they receive chemotherapy treatment compared to men who receive treatment with surgery alone.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients|
|Study Start Date:||September 2008|
|Study Completion Date:||July 2012|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
Testicular cancer patients who have received surgery and are scheduled for surveillance
Testicular cancer patients who have received surgery and are scheduled for chemotherapy
The aim of this pilot study is to examine global and regional LV systolic and diastolic function, cardiac output, cardiac reserve, VO2peak and CVD risk profile in males recently diagnosed with testicular cancer treated with surgery alone or surgery and chemotherapy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00705094
|Cross Cancer Institute|
|Edmonton, Alberta, Canada, T6G 1Z2|
|Principal Investigator:||Mark Haykowsky, PhD||University of Alberta|